GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2014
Melanoma, version 4.2014.
Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 78 citations in OpenAlex.
- Results of a phase II, open-label, non-comparative study of intralesional PV-10 followed by radiotherapy for the treatment of in-transit or metastatic melanoma.Journal of surgical oncology · 2017Trial
- Influence of different positioning of a local pain catheter on postoperative pain after paramedian laparotomy-a blinded, randomized trial.Langenbeck's archives of surgery · 2016Trial
- Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.Scientific reports · 2020Article
- MicroRNA-153-3p sensitizes melanoma cells to dacarbazine by suppressing ATG5-mediated autophagy and apoptosis.Translational cancer research · 2020Article
- Patterns of failure following the excision of in-transit lesions in melanoma and the influence of excisional margins.Journal of surgical oncology · 2018Article
- Stratifying SLN incidence in intermediate thickness melanoma patients.American journal of surgery · 2018Article
- Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.BMC cancer · 2018Article
- MicroRNA-150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4.Oncology letters · 2018Article
- Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study.Annals of surgical oncology · 2017Article
- Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?Clinical & experimental metastasis · 2017Article
- Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision.JAMA dermatology · 2017Article
- Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis.JCO precision oncology · 2017Article
- Can multispectral optoacoustic tomography replace sentinel lymph biopsy in melanoma?Annals of translational medicine · 2016Article
- Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma.Melanoma research · 2016Article
- Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity.Annals of surgical oncology · 2016Article
- Effects of a novel Nodal-targeting monoclonal antibody in melanoma.Oncotarget · 2015Article
- Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.The Journal of clinical investigation · 2015Review
- Analysis of melanoma recurrence following a negative sentinel lymph node biopsy.Melanoma management · 2015Review
- NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.Diagnostic pathology · 2015Article
Corrections and comments
- Commented on by
Authors and funding
29 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.